FN1 and pulmonary fibrosis: Understanding the mechanisms by which ECM fibronectin influences cell and tissue responses to PDGF is critical to designing targeted therapies for the wide range of pathologies characterized by aberrant PDGF signaling, including asthma, liver cirrhosis, atherosclerosis, pulmonary fibrosis, cancer, and chronic wounds.